79 filings
Page 3 of 4
8-K
6gp310a
11 Mar 21
PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab
8:08am
8-K
84ti4i brhb1mf
28 Jan 21
Other Events
8:11am
8-K
2ukok08whfxxp15xp
27 Jan 21
Other Events
4:11pm
8-K
9fh30d8n
12 Nov 20
PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results
4:12pm
8-K
ou84u4om78f0d61 nk6
23 Oct 20
PhaseBio Provides Pemziviptadil (PB1046) Program Update
8:20am
8-K
oggi191 0tt416
6 Oct 20
Other Events
8:09am
8-K
n00zcwwuc
11 Aug 20
PhaseBio Reports Recent Business Highlights and Second-Quarter 2020 Financial Results
4:09pm
8-K
mvq39
16 Jul 20
Other Events
4:10pm
8-K
kwe o055s
5 Jun 20
Submission of Matters to a Vote of Security Holders
4:36pm
8-K
z53g6bjfmfi6kzjlio85
27 May 20
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients
4:11pm
8-K
0t6hme9j
12 May 20
PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights
4:08pm
8-K
e38uymn 6v09
30 Mar 20
PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights
8:08am
8-K
h8x3xxwkr0blxu78j
20 Mar 20
Entry into a Material Definitive Agreement
4:13pm
8-K
vlrgrwr7pb 8e3f7y7
4 Mar 20
Regulation FD Disclosure
4:06pm
8-K
el11nq0h
13 Feb 20
PhaseBio Appoints Alex C. Sapir to Board of Directors
4:07pm
8-K
0mucgefb peurxtsry
11 Feb 20
PhaseBio Announces European Regulatory Update for PB2452
8:08am
8-K
v4upv030 ycj8g1hdv6l
4 Feb 20
PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at 14th Pulmonary Vascular Research Institute World Congress
4:08pm
8-K
kcws uunsnz75
13 Jan 20
PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension
4:07pm
8-K
wl33rs8yji3 etrvk
10 Jan 20
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
9:07am
8-K
ir5l 8fwl
14 Nov 19
PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress
8:16am